SCM
IBRX icon

Sterling Capital Management’s ImmunityBio IBRX Stock Holding History

Sterling Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9K Sell
1,358
-1,935
-59% -$14.6K ﹤0.01% 2132
2026
Q1 		$25.3K Sell
3,293
-986
-23% -$6.75K ﹤0.01% 1915
2025
Q4 		$8.47K Buy
4,279
+1,036
+32% +$2.35K ﹤0.01% 2687
2025
Q3 		$7.98K Buy
3,243
+1,818
+128% +$4.68K ﹤0.01% 2613
2025
Q2 		$3.76K Buy
1,425
+730
+105% +$1.96K ﹤0.01% 2667
2025
Q1 		$2.09K Sell
695
-518
-43% -$1.57K ﹤0.01% 2580
2024
Q4 		$3.1K Buy
1,213
+1,000
+469% +$4.17K ﹤0.01% 2640
2024
Q3 		$792 Buy
+213
New +$986 ﹤0.01% 2660

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sterling Capital Management's IBRX Position: Q2 2026 in Review

Sterling Capital Management reduced its ImmunityBio (IBRX) stake by 59% in Q2 2026, selling an estimated $14.6K and leaving 1,358 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2132.

Sterling Capital Management first reported a position in IBRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $25.3K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Sterling Capital Management held 1,358 shares of ImmunityBio worth $11.9K as of Q2 2026.
  • Sterling Capital Management sold 1,935 ImmunityBio shares in Q2 2026, an estimated $14.6K.
  • ImmunityBio made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2132 holding.
  • Sterling Capital Management first reported a position in ImmunityBio in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's ImmunityBio position peaked at $25.3K in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.